All In Biotech

Drug Trial Radar · NCT07456826

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

A Phase 4, Multisite, Randomized, Double-Masked, Well-Controlled Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections: The QUELL Study

Last checked: Nov 20, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 236 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

236

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Harrow IncIndustry
Sponsor type
Industry
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined with subconjunctival lidocaine 2%) for ocular surface anesthesia during intravitreal injection procedures. Adult participants scheduled to undergo unilateral intravitreal injection of an FDA-approved anti-vascular endothelial growth factor (anti-VEGF) agent for retinal conditions will be randomized in a 1:1 ratio to receive either IHEEZO with a sham subconjunctival procedure or routine anesthesia. The primary objective is to determine whether IHEEZO is non-inferior to routine anesthesia in achieving successful ocular surface anesthesia, defined as a participant-reported pain score of 0 or 1 (on a 0-5 ordinal pain scale) immediately before and immediately after intravitreal injection. Secondary outcomes include individual and cumulative pain scores, change from baseline in dry eye symptoms measured by the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and ocular safety assessments through Day 7 follow-up.

Conditions

  • Diabetic Macular Edema (DME)
  • Age-Related Macular Degeneration (AMD)
  • Retinal Vein Occlusion
  • Diabetic Retinopathy (DR)

Interventions

  • Chloroprocaine Ophthalmic Gel 3% (IHEEZO)Drug

    Preservative-free chloroprocaine hydrochloride ophthalmic gel 3% administered as 3 topical drops to the study eye prior to intravitreal injection.

  • Sham Subconjunctival InjectionProcedure

    Sham procedure performed using a syringe with a blunt-tipped cannula that does not contact the conjunctiva, performed to maintain masking prior to intravitreal injection.

  • Proparacaine Hydrochloride Ophthalmic Solution 0.5%Drug

    Topical proparacaine hydrochloride ophthalmic solution 0.5% administered as 3 drops to the study eye prior to intravitreal injection.

  • Lidocaine Hydrochloride Injection 2%Drug

    Subconjunctival injection of lidocaine hydrochloride 2% administered after topical proparacaine and prior to intravitreal injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Achieving Successful Ocular Surface AnesthesiaTime frame: Immediately before and immediately after intravitreal injection (Day 1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tyler Retina Research Institute

    Tyler, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.